Iovance Biotherapeutics to Present at Upcoming Conferences
March 01 2024 - 5:00PM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology
company focused on innovating, developing, and delivering novel
polyclonal tumor infiltrating lymphocyte (TIL) therapies for
patients with cancer, today announced that senior leadership plans
to present at the following conferences:
- TD Cowen’s 44th Annual Health Care ConferenceFireside Chat:
March 4, 2024 at 11:10 a.m. ETBoston, MA
- Barclays 26th Annual Global Healthcare ConferenceFireside Chat:
March 12, 2024 at 10:45 a.m. ETMiami, FL
- H.C. Wainwright 2nd Annual Cell Therapy Virtual
ConferenceFireside Chat: March 26, 2024 at 1:30 p.m. ETVirtual
The live and archived webcasts will be available at
https://ir.iovance.com/news-events/events-presentations.
About Iovance Biotherapeutics, Inc.Iovance
Biotherapeutics, Inc. aims to be the global leader in innovating,
developing, and delivering tumor infiltrating lymphocyte (TIL)
therapies for patients with cancer. We are pioneering a
transformational approach to cure cancer by harnessing the human
immune system’s ability to recognize and destroy diverse cancer
cells in each patient. The Iovance TIL platform has demonstrated
promising clinical data across multiple solid tumors. Iovance’s
Amtagvi™ is the first FDA-approved T cell therapy for a solid tumor
indication. We are committed to continuous innovation in cell
therapy, including gene-edited cell therapy, that may extend and
improve life for patients with cancer. For more information, please
visit www.iovance.com.
Amtagvi™ and its accompanying design marks, Proleukin®,
Iovance®, and IovanceCares™ are trademarks and registered
trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries.
All other trademarks and registered trademarks are the property of
their respective owners.
Forward-Looking StatementsCertain matters
discussed in this press release are “forward-looking statements” of
Iovance Biotherapeutics, Inc. (hereinafter referred to as the
“Company,” “we,” “us,” or “our”) within the meaning of the Private
Securities Litigation Reform Act of 1995 (the “PSLRA”). Without
limiting the foregoing, we may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “forecast,”
“guidance,” “outlook,” “may,” “could,” “might,” “will,” “should,”
or other words that convey uncertainty of future events or outcomes
and are intended to identify forward-looking statements.
Forward-looking statements are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future
developments, and other factors believed to be appropriate.
Forward-looking statements in this press release are made as of the
date of this press release, and we undertake no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks,
uncertainties, and other factors, many of which are outside of our
control, that may cause actual results, levels of activity,
performance, achievements, and developments to be materially
different from those expressed in or implied by these
forward-looking statements. Important factors that could cause
actual results, developments, and business decisions to differ
materially from forward-looking statements are described in the
sections titled "Risk Factors" in our filings with the U.S.
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and
include, but are not limited to, the following substantial known
and unknown risks and uncertainties inherent in our business: the
risks related to our ability to successfully commercialize our
products, including Amtagvi and Proleukin, for which we obtain U.S.
Food and Drug Administration (“FDA”), European Medicines Agency
(“EMA”), or other regulatory authority approval; the risk that the
EMA or other regulatory authorities may not approve or may delay
approval for our biologics license application (“BLA”) submission
for lifileucel in metastatic melanoma; the acceptance by the market
of our products, including Amtagvi and Proleukin, and their
potential pricing and/or reimbursement by payors, if approved (in
the case of our product candidates), in the U.S. and other
international markets and whether such acceptance is sufficient to
support continued commercialization or development of our products,
including Amtagvi and Proleukin, or product candidates,
respectively; our ability or inability to manufacture our therapies
using third party manufacturers or at our own facility may
adversely affect our commercial launch; the results of clinical
trials with collaborators using different manufacturing processes
may not be reflected in our sponsored trials; the risk regarding
the successful integration of the recent Proleukin acquisition; the
risk that the successful development or commercialization of our
products, including Amtagvi and Proleukin, may not generate
sufficient revenue from product sales, and we may not become
profitable in the near term, or at all; the risk that future
competitive or other market factors may adversely affect the
commercial potential for Amtagvi or Proleukin; the risks related to
the timing of and our ability to successfully develop, submit,
obtain, or maintain FDA, EMA, or other regulatory authority
approval of, or other action with respect to, our product
candidates; whether clinical trial results from our pivotal studies
and cohorts, and meetings with the FDA, EMA, or other regulatory
authorities may support registrational studies and subsequent
approvals by the FDA, EMA, or other regulatory authorities,
including the risk that the planned single arm Phase 2 IOV-LUN-202
trial may not support registration; preliminary and interim
clinical results, which may include efficacy and safety results,
from ongoing clinical trials or cohorts may not be reflected in the
final analyses of our ongoing clinical trials or subgroups within
these trials or in other prior trials or cohorts; the risk that
enrollment may need to be adjusted for our trials and cohorts
within those trials based on FDA and other regulatory agency input;
the risk that the changing landscape of care for cervical cancer
patients may impact our clinical trials in this indication; the
risk that we may be required to conduct additional clinical trials
or modify ongoing or future clinical trials based on feedback from
the FDA, EMA, or other regulatory authorities; the risk that our
interpretation of the results of our clinical trials or
communications with the FDA, EMA, or other regulatory authorities
may differ from the interpretation of such results or
communications by such regulatory authorities (including from our
prior meetings with the FDA regarding our non-small cell lung
cancer clinical trials); the risk that clinical data from ongoing
clinical trials of Amtagvi will not continue or be repeated in
ongoing or planned clinical trials or may not support regulatory
approval or renewal of authorization; the risk that unanticipated
expenses may decrease our estimated cash balances and forecasts and
increase our estimated capital requirements; the effects of the
COVID-19 pandemic; and other factors, including general economic
conditions and regulatory developments, not within our control.
CONTACTSIovance Biotherapeutics,
Inc:Sara Pellegrino, IRCSenior Vice President, Investor
Relations & Corporate Communications650-260-7120 ext.
264Sara.Pellegrino@iovance.com
Jen SaundersSenior Director, Investor Relations & Corporate
Communications267-485-3119Jen.Saunders@iovance.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024